Bringing the fundamentals into focus…
Back to Inhibrx Biosciences, Inc.
How Inhibrx Biosciences, Inc. stacks up
INBX · against 1,216 other Healthcare companies
Growth
11/ 100
Near the bottom of its peers.
Ranked #1,078 of 1,217 · scores higher than 11% of peers
Bars: peers in each 10-point band of the growth score122 peers with a growth score of 10–19, including INBX · Click a bar to see the companies
Why growth scores 11?
Weighted metrics compared with all Healthcare companies.Mainly because of its revenue growth and 3-year revenue growth, which are weaker than most Healthcare peers.
- slower revenue growth over the last year: weaker than 100% of peers. Revenue growth: -100.0% vs peer median 6.1%
- slower revenue growth over three years: weaker than 71% of peers. 3-year revenue growth: -0.0% vs peer median 5.8%
- Still loss-making, but the loss per share narrowed. Earnings per share growth: — vs peer median 9.8%
Metric by metric
Position: dot = INBX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | INBX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 1,243 reported | -100.0% | 6.1% | 0% | 33% | |
| Earnings per share growthHigher is better · 682 reported | Not reported | 9.7% | — | — | 33% |
| 3-year revenue growthHigher is better · 1,192 reported | -0.0% | 5.8% | 29% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around INBX| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 3.1B EUR (≈$3.4B) | 100 | 100 | |
| 1 | 464M USD | 100 | 53 | |
| 3 | 8.9B HKD (≈$1.1B) | 99 | 61 | |
| 3 | 1.8B HKD (≈$224M) | 99 | 59 | |
| 3 | 7.2B TWD (≈$224M) | 99 | 41 | |
| 1,078 | 2.8B CNY (≈$399M) | 11 | 47 | |
| 1,078 | 2.8B CNY (≈$396M) | 11 | 29 | |
| 1,078 | 6.5B CNY (≈$911M) | 11 | 62 | |
| 1,078 | 143.3B JPY (≈$975M) | 11 | 61 | |
| 1,078 | 1.2B USD | 11 | 6 | |
| 1,078 | 157M USD | 11 | ||
| 1,090 | 3.1B CNY (≈$439M) | 10 | 25 | |
| 1,090 | 6.7B CNY (≈$938M) | 10 | 30 | |
| 1,090 | 6.2B CNY (≈$861M) | 10 | 35 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score